Qurient Announces Collaboration Agreement with MSD

19 September 2022 | Monday | News

To Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)
Image Source : Public Domain

Image Source : Public Domain

  • Q901 is a novel highly selective CDK7 inhibitor
  • Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103)
  • The phase 1/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors

-Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), for clinical study of Q901, a selective CDK7 inhibitor in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Under this agreement, Qurient will conduct a phase 1/2 study in the U.S. to evaluate safety and efficacy of Q901 in combination with KEYTRUDA for the treatment of selected advanced solid tumors.

“We are pleased to collaborate with MSD to evaluate Q901 in combination with KEYTRUDA for advanced solid tumors where limited treatment options are currently available. Q901 shows very effective tumor growth inhibition through cell cycle regulation and triggers genomic instability, which may set synthetic lethality for anti-PD-1 therapy. The Q901 and anti-PD-1 antibody combination showed beneficial effect in preclinical models, and we expect the same clinical benefits,” said Kiyean Nam, Ph.D., CEO of Qurient. “The clinical collaboration with MSD on Q901-KEYTRUDA combination follows on clinical collaboration on Q702-KEYTRUDA combination agreement announced in November 2021, and they are important milestones for patients who have had few treatment options, and Qurient’s two lead oncology assets.”

Terms of the collaboration were not disclosed.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme, LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in